Loading organizations...

§ Private Profile · Boston, MA, USA
Marketplace platform connecting life science companies with vetted on-demand experts for pharmaceutical, biotech, and medical device projects.
Founded in 2016 by Rahul Chaturvedi and Leaya Martelli, Boston-based Clora operates a marketplace connecting pharmaceutical, biotechnology, and medical device companies with vetted, on-demand life sciences experts. The platform streamlines talent acquisition for projects ranging from early drug discovery to late-stage commercialization, utilizing a community of thousands of specialized suppliers to reduce traditional recruitment costs by 70 percent. In February 2021, the organization expanded its technological capabilities by acquiring the artificial intelligence firm Legit AI, bringing its founder Matt Osman on as Vice President of Strategy. This strategic acquisition integrated advanced artificial intelligence to further optimize Clora's matching and staff augmentation services for hundreds of top-tier biotech and pharma firms. The company has raised over four million dollars, including a seed round led by Spark Capital with participation from Social Capital, Ludlow Ventures, and Notation Capital.
Clora has raised $5.0M across 1 funding round.
Clora has raised $5.0M in total across 1 funding round.
Clora is a technology platform that matches life science companies with on-demand, flexible expertise from a global network of vetted consultants.[1][2][3] It serves pharmaceutical, biotechnology, and medical device firms by addressing talent shortages for projects spanning drug discovery to commercialization, offering faster matching (within days), higher fill rates (100%), and cost efficiency compared to traditional staffing.[1][2][3] With 27-32 employees and under $5 million in revenue and funding, Clora demonstrates steady growth momentum through proprietary AI-driven matching and partnerships like Science Exchange.[3][4]
Founded in 2015 or 2016 by industry veterans frustrated with inefficient hiring in life sciences, Clora emerged from real-world pain points like delayed projects, blown budgets, and therapy delays due to talent gaps.[1][2][3][4] Headquartered in Boston, Massachusetts (with some records noting Cambridge), the team drew from experience at firms like Merck, Johnson & Johnson, Pfizer, Novartis, and the FDA to build a platform prioritizing domain expertise and speed.[2][3][4] Early traction came from targeting 300+ skillsets across the product lifecycle, achieving a 100% match success rate and rapid adoption by startups to corporates.[2][3]
Clora rides the wave of talent scarcity in life sciences amid booming biotech/pharma R&D, where flexible staffing demand surges due to project volatility and global competition.[1][2] Timing aligns with post-pandemic innovation in drug discovery, gene therapy, and digital health, amplified by remote work trends and AI talent platforms.[3][6] Market forces like rising development costs and regulatory pressures favor Clora's rapid, precise matching, reducing delays in therapies reaching patients.[2] It influences the ecosystem by boosting productivity for underserved startups and giants, fostering a consultant community, and expanding into IT for life sciences (e.g., secure platforms, process development).[4][6]
Clora is poised to scale as life science R&D funding grows and AI matching evolves, potentially capturing more of the fragmented staffing market through deeper IT integrations and global expansion.[2][6] Trends like personalized medicine, gene editing, and outsourced expertise will shape its path, with opportunities in emerging areas like AI-driven drug discovery.[1][6] Its influence may evolve from niche matcher to ecosystem enabler, powering faster innovation cycles for therapies—directly tying back to solving the talent frictions that birthed the platform.[2][3]
Clora has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in December 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2017 | $5M Seed | John Melas Kyriazi | Asylum Ventures, BoxGroup, Spero Ventures, Sean Flynn, ISeed Ventures, KohFounders, Ludlow Ventures, Notation Capital, Social Capital, V1.VC | Announced |
Clora has raised $5.0M in total across 1 funding round.
Clora's investors include John Melas-Kyriazi, Asylum Ventures, BoxGroup, Spero Ventures, Sean Flynn, iSeed Ventures, KohFounders, Ludlow Ventures, Notation Capital, Social Capital, V1.VC.